Damoctocog alfa pegol

Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A.^[5][6]

Damoctocog alfa pegol

Clinical data
Trade names	Jivi
Other names	BAY94-9027, antihemophilic factor (recombinant), pegylated-aucl
AHFS/Drugs.com	Monograph
License data	US DailyMed: Damoctocog alfa
Pregnancy category	AU: B2[1]
Routes of administration	Intravenous
ATC code	B02BD02 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1][2][3] CA: ℞-only / Schedule D[4] US: ℞-only[5] EU: Rx-only[6] In general: ℞ (Prescription only)
Identifiers
CAS Number	1363853-26-2
DrugBank	DB14700
UNII	BY4TSK952Y
KEGG	D10759
Chemical and physical data
Formula	C7445H11318N1984O2184S69
Molar mass	165774.28 g·mol−1

The most common side effects include headache, cough, nausea, and fever.^[5]

Damoctocog alfa pegol was approved for medical use in the United States in August 2018,^[7] and in the European Union in November 2018.^[6][8]

Medical uses

In the United States damoctocog alfa pegol is indicated for use in previously treated people twelve years of age and older with hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes; perioperative management of bleeding; or routine prophylaxis to reduce the frequency of bleeding episodes.^[7]

In the European Union, damoctocog alfa pegol is indicated for the treatment and prophylaxis of bleeding in previously treated people twelve years of age and older with hemophilia A (congenital factor VIII deficiency).^[6]